Heron Therapeutics (NASDAQ:HRTX) Upgraded to Buy at StockNews.com

Heron Therapeutics (NASDAQ:HRTX) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Tuesday.

Separately, Needham & Company LLC restated a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a report on Wednesday, December 4th.

Heron Therapeutics Trading Up 3.8 %

Shares of HRTX stock opened at $1.63 on Tuesday. The company has a market capitalization of $247.92 million, a price-to-earnings ratio of -9.06 and a beta of 1.60. The firm has a 50-day moving average price of $1.47 and a 200 day moving average price of $1.93. Heron Therapeutics has a twelve month low of $1.04 and a twelve month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The firm had revenue of $32.81 million during the quarter, compared to analyst estimates of $36.40 million. During the same period in the prior year, the firm earned ($0.17) EPS. As a group, research analysts predict that Heron Therapeutics will post -0.13 earnings per share for the current year.

Institutional Investors Weigh In On Heron Therapeutics

A number of institutional investors have recently bought and sold shares of HRTX. Congress Park Capital LLC boosted its holdings in shares of Heron Therapeutics by 24.1% in the 4th quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company’s stock valued at $3,757,000 after purchasing an additional 477,417 shares during the last quarter. Clearline Capital LP raised its position in shares of Heron Therapeutics by 48.9% in the 3rd quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock worth $4,431,000 after buying an additional 731,246 shares during the period. Marshall Wace LLP boosted its holdings in Heron Therapeutics by 256.2% in the second quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock valued at $6,164,000 after acquiring an additional 1,266,697 shares during the last quarter. AQR Capital Management LLC grew its position in Heron Therapeutics by 1,460.9% during the second quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock valued at $2,125,000 after acquiring an additional 568,238 shares during the period. Finally, GSA Capital Partners LLP increased its stake in Heron Therapeutics by 18.4% during the third quarter. GSA Capital Partners LLP now owns 512,736 shares of the biotechnology company’s stock worth $1,020,000 after acquiring an additional 79,680 shares during the last quarter. 80.01% of the stock is currently owned by hedge funds and other institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.